Observing bowel cleansing effects in patients with renal impairment
Official title: Clinical Registry of Adverse Effects in the Preparation for Colonoscopy in Patients With Advanced Renal Failure
Run by Parc de Salut Mar · NCT05349851 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to see how bowel preparation for colonoscopy affects kidney function in patients with advanced kidney failure, especially those on dialysis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 237 (estimated) |
| Sponsor | Parc de Salut Mar Academic / other |
| Locations | 2 sites (Manresa, Cataluña and 1 other locations) |
| Trial ID | NCT05349851 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are outpatients aged 18-80 with moderate to severe renal impairment scheduled for a colonoscopy.
✕Probably not a fit
Patients with conditions such as severe constipation, active intestinal disease, or those who have undergone partial or total colectomy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to create a clinical registry to assess the renal adverse effects associated with bowel preparation for colonoscopy in patients with advanced renal failure. It will involve collecting data on kidney function, bowel-cleansing efficacy, and patient tolerability during routine clinical practice. The study will include outpatients scheduled for colonoscopy and will analyze the incidence of renal adverse effects, particularly in those undergoing hemodialysis or peritoneal dialysis. A sample size of 237 subjects will be targeted to ensure robust findings.
Why it matters
Potential benefit: If successful, this study could improve the safety and tolerability of bowel cleansing procedures in patients with renal impairment.
How similar studies have gone: While bowel preparation in renal impairment has been considered safe, this study is novel in its prospective assessment of renal adverse effects in routine clinical practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Outpatients or hospitalized patients with previously scheduled colonoscopy with any indication: screening, follow-up or symptoms. * Diagnosis of stage 3B-5D chronic renal failure (creatinine clearance less than 45 ml / min / 1.73 m2). Exclusion Criteria: * Age less than 18 years or greater than 80 years * Partial or total colectomy * Severe constipation * Active inflammatory bowel disease * Severe hepatic impairment (Child Pugh Classification C) * Pregnancy or breastfeeding * Refusal to authorize the clinical registration of the information
Where it's running
-
Althaia Xarxa Assistencial Universitària de Manresa
Manresa, Cataluña, Spain Recruiting -
Hospital Reina Sofía
Tudela, Navarra, Spain Recruiting
Study contacts
- Principal investigator: Marco A Álvarez, MD, PhD — Althaia Xarxa Assistencial Universitària de Manresa; Institut Hospital del Mar d'investigacions mèdiques, Barcelona.
- Study coordinator: Marco A Álvarez, MD, PhD
- Email: maalvarez@althaia.cat
- Phone: 0034 933160595
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rilzabrutinib in adults with severe kidney impairment vs. normal kidney function
This study tests how rilzabrutinib behaves in the body and its safety in adults with severe kidney impairment compared to healthy adults.
-
Ribupatide PK in People with Kidney Impairment
This study tests how a single shot of ribupatide behaves in the body for people with severe kidney problems compared to those with normal kidney function.
-
Renal function and afabicin; how kidney health changes drug levels
This trial tests how different levels of kidney function affect the blood levels of afabicin given as a pill or IV after a single dose.
-
Safety and how the body handles RO7795081 in people with kidney problems
This study tests how RO7795081 behaves in the body and its safety after a single dose in people with normal kidney function and those with renal impairment.
-
Testing D-2570 in adults with varying kidney function
This study tests a single dose of D-2570 in adults aged 18–70 with different levels of kidney function to see how the drug behaves in the body.
-
Safety and blood levels of INCB123667 in adults with severe kidney problems
This study tests whether oral INCB123667 is safe and how it behaves in the body for adults with severe renal impairment or end-stage kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.